LDL particle size and antioxidant HDL function improve after sustained virological response in patients with chronic HCV

Ann Hepatol. 2022 Jan-Feb;27(1):100555. doi: 10.1016/j.aohep.2021.100555. Epub 2021 Oct 6.

Abstract

HCV infection is associated with an increased incidence of cardiovascular (CV) events. Mechanisms underlying this association remain unknown. In our study, twenty HCV patients (median age 60.5 years, 65% male and 80% with cirrhosis) were evaluated prior, during and after direct-acting antiviral treatment. Ninety percent of patients achieved sustained virological response (SVR). Significant changes were observed in LDL particle size index, measured by LDL-C/apoB ratio, which increased after treatment (p = 0.023). In addition, HDL antioxidant capacity improved gradually from 34.4% at baseline to 42.4% at 4 weeks (p = 0.011), 65.9% at end of treatment EOT (p = 0.002) and remained elevated at 12-week (p = 0.001) after EOT compared to baseline values. Our findings suggest that a shift to a less atherogenic lipid profile may be a possible mechanism associated with CV risk reduction in patients with HCV infection achieving SVR.

Keywords: Cardiovascular risk; Direct-acting antivirals; HDL antioxidant capacity; HDL functionality; Hepatitis C virus; LDL particle size; Sustained virological response.

Publication types

  • Observational Study

MeSH terms

  • Aged
  • Antioxidants / therapeutic use*
  • Antiviral Agents / therapeutic use*
  • Female
  • Follow-Up Studies
  • Hepacivirus / isolation & purification*
  • Hepatitis C, Chronic / blood*
  • Hepatitis C, Chronic / drug therapy
  • Humans
  • Lipoproteins, HDL / metabolism*
  • Lipoproteins, LDL / blood*
  • Male
  • Middle Aged
  • Particle Size
  • Prospective Studies
  • Sustained Virologic Response*
  • Treatment Outcome

Substances

  • Antioxidants
  • Antiviral Agents
  • Lipoproteins, HDL
  • Lipoproteins, LDL